Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Learn more about this revolutionary cancer treatment.
Understand the Basics
Meet the CRI scientists committed to the development of immunotherapy.
The immune system is capable of dynamically adapting its defenses to any target. These extraordinary capabilities allow immunotherapies to unleash a powerful immune attack on cancer that adapts to the unique and ever-changing characteristics of each tumor, anywhere in the body.
Immunotherapy holds the potential to exceed the results of established cancer treatments, becoming more targeted and more effective than many chemotherapies—with fewer side effects.
Cancer immunotherapy—treatments that harness and enhance the innate powers of the immune system to fight cancer—represents the most promising new cancer treatment approach since the devevlopment of the first chemotherapies in the 1940s.
For more than 60 years, the Cancer Research Institute (CRI) has been the pioneer in advancing this new class of treatment.
Learn About CRI's Impact
Immunotherapy enables the immune system to recognize and target cancer cells, making it a universal answer to cancer.
Immunotherapy has been an effective treatment for patients with certain types of cancer that have been resistant to chemotherapy and radiation treatment (e.g., melanoma)
Immunotherapy can “train” the immune system to remember cancer cells. This “immunomemory” may result in longer-lasting remissions
Clinical studies on long-term overall survival have shown that the beneficial responses to cancer immunotherapy treatment are durable—that is, they can be maintained even after treatment is completed
CLIP Grants available for qualified scientists working to explore clinical questions aimed at improving effectiveness of immunotherapies.
Apply for research funding and join our mission to cure all cancers.
Find a Clinical Trial by cancer type to learn about available therapies.
Create a profile and fill out a questionnaire to identify immunotherapy clinical trials you may be eligible for.
CALLING HOURS | M-F 8:30 a.m. to 6 p.m. ET
Se habla espanol
Request a call from a Clinical Trial Navigator
National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006
(800) 992-2623(212) 832-9376Staff Directory
Atezolizumab’s third approval in the last year provides an important treatment option for a neglected population of patients with bladder cancer
TIME magazine honors Dr. Allison’s development of the first checkpoint immunotherapy, which has led to a revolution in cancer treatment.